The Most Affordable Compounded Tirzepatide Online in 2026
Compounded tirzepatide runs about $199-297/month across legitimate providers, with MEDVi reporting the lowest published self-pay near $199 and Mochi at $278 all-in. All competitor figures are Provider Reported; none is first-party verified yet.
- Compounded tirzepatide ranges ~$199-297/mo across legitimate providers.
- MEDVi reports the lowest published self-pay near $199 (Verification Pending).
- Mochi is ~$278 all-in ($199 medication + $79 required membership).
- No competitor tirzepatide price is first-party verified yet — all Provider Reported.
The pricing landscape
Compounded tirzepatide clusters between about $199 and $297 per month across legitimate telehealth providers. The floor sits higher than compounded semaglutide because tirzepatide's active ingredient is harder to source.
MEDVi reports the lowest published self-pay price, near $199 per month for lower doses, though this is Verification Pending in our ledger. Mochi Health charges $199 for medication plus a required $79 membership, making its all-in cost about $278.
Henry Meds runs about $297 month-to-month, with dose surcharges above the starting dose.
Why nothing is 'verified' yet
An important honesty point: none of these competitor tirzepatide prices is first-party verified in our evidence ledger. We label them Provider Reported or Verification Pending because we have not captured them directly from the provider's own checkout with the full field set.
This matters because provider sites frequently render pricing client-side or change it without notice, and a price from a review aggregator is not the same as a captured price. We do not mark a competitor price Verified until we capture it ourselves.
So this ranking is a category comparison of reported prices, not a verified leaderboard. Treat the numbers as starting points to confirm directly.
| Provider | Medication | All-in | Status |
|---|---|---|---|
| MEDVi | $199 (starting) | $199 | Verification Pending |
| Eden Health | $249-296 | $249-296 | Verification Pending |
| Mochi Health | $199 | $278 (+$79) | Provider Reported |
| Henry Meds | $297 (m2m) | $297+ | Provider Reported |
Comparing effective cost
As with semaglutide, the headline tirzepatide price is not the whole cost. A required membership, dose surcharge, or shipping fee changes the real monthly number. Mochi's $199 medication becomes $278 with its required membership.
Model your cost at your target maintenance dose, because tiered programs climb as you titrate. A program with a low entry price but steep dose surcharges can end up the most expensive at maintenance.
The table below puts the main providers on an all-in basis for comparison.
Beyond price
The cheapest reported tirzepatide is not automatically the best choice. Pharmacy transparency, dose coverage, cancellation terms, and clinical oversight all matter. A slightly higher price from a provider that names its state-licensed pharmacy and holds flat pricing can be better value.
Because tirzepatide is compounded and not FDA-approved, provenance matters especially: confirm the dispensing pharmacy and that a real prescription pathway exists.
Sub-$200 maintenance pricing is a flag to scrutinize, not automatically trust.
| Label | Meaning |
|---|---|
| Verified | First-party captured (none yet for competitor tirz) |
| Provider Reported | Provider-stated, not captured by us |
| Verification Pending | Only secondary sources so far |
The bottom line
Compounded tirzepatide runs about $199-297 per month, with MEDVi reporting the lowest self-pay and Mochi at $278 all-in. All competitor figures are Provider Reported, not first-party verified.
Compare effective cost at your maintenance dose, include required fees, and weigh pharmacy transparency alongside price. Confirm current pricing directly, since our competitor figures are reported rather than captured.
Compounded tirzepatide is not FDA-approved and requires a clinician's prescription.
Frequently asked questions
What is the cheapest compounded tirzepatide?
MEDVi reports the lowest published self-pay near $199/month, but this is Verification Pending. Mochi is ~$278 all-in. Confirm directly, since none is first-party verified.
Why is no tirzepatide price marked Verified?
Because we have not captured any competitor tirzepatide price first-party with the full field set. We label them Provider Reported or Verification Pending until we do.
Why is tirzepatide more expensive than semaglutide?
Its active ingredient is harder to source, which raises the price floor across all legitimate providers.
Is sub-$200 tirzepatide a good deal?
Scrutinize it. Sustained maintenance pricing below the market floor can signal sourcing or safety problems rather than a genuine bargain.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- Provider pricing and manufacturer sources, September 2026.
- Forbes Health, U.S. News reviews, July 2026.
- Evidence policy: evidence policy.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $139 to $399 a month across the 12 programmes we can price, with a median of $298. The spread between cheapest and dearest is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $139 on its 12-month plan; Found follows at $169 (12-month prepaid). Half the market sits below $298 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
3 programmes additionally advertise a tirzepatide microdose, the cheapest at $147 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
What we do not claim in tirzepatide
The tirzepatide figures on this page span $139 to $399 a month across 12 programmes.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. 3 programmes advertise a tirzepatide microdose, the cheapest at $147 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded tirzepatide?
NexLife at $139 a month at a standard therapeutic dose on the 12-month plan ($1,668 total), captured 2026-09-04. 6-month $149; 3-month $159; month-to-month $169. No membership fee, flat at every covered dose. Verified. The next-cheapest is Found at $169, which requires prepaying twelve months (Provider Reported).
What does compounded tirzepatide normally cost?
$139 to $399 a month across 12 programmes, with a median of $298. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.